Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARC0812
- Development stage
- Preclinical
- Lead developer
- ARC Therapies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
ARC0812 (brand name Lux) is a research-stage live biotherapeutic product (LBP) being developed by ARC Therapies Inc., a startup originating from the National Cancer Center Japan. The drug's active ingredient is YB328, a specific gut bacterial strain identified by Dr. Hiroyoshi Nishikawa's research group as being prevalent in cancer patients who respond positively to immune checkpoint inhibitors. ARC0812 is intended to serve as an immune adjuvant in human cancer immunotherapy, aiming to bolster the immune system's response when administered alongside antigen-targeting agents. ARC Therapies is currently conducting preclinical evaluations to determine optimal administration methods and therapeutic efficacy for eventual clinical development.
- Brand names
- Lux
- Other names
- YB328YB-328YB 328
Beyond the preview
Go deeper on ARC0812.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARC0812.